CEREBROSPINAL-FLUID INHIBITS ALZHEIMER BETA-AMYLOID FIBRIL FORMATION IN-VITRO

被引：59
|
作者：
WISNIEWSKI, T [1 ]
CASTANO, E [1 ]
GHISO, J [1 ]
FRANGIONE, B [1 ]
机构：
[1] NYU MED CTR,DEPT PATHOL,NEW YORK,NY 10016
来源：
ANNALS OF NEUROLOGY | 1993年 / 34卷 / 04期
关键词：
D O I：
10.1002/ana.410340422
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
Alzheimer's disease is characterized by the deposition of beta-protein (Abeta) as amyloid. Recently, it was found that Abeta is a normal component of serum and cerebrospinal fluid. Synthetic peptides homologous to Abeta form amyloid-like fibrils spontaneously in water or physiological solutions. Using a peptide homologous to Abeta1-40, we find that fibril formation is inhibited by the presence of cerebrospinal fluid.
引用
收藏
页码：631 / 633
页数：3
相关论文
共 50 条
  • [31] Crocetin inhibits beta-amyloid fibrillization and stabilizes beta-amyloid oligomers
    Ahn, Joon Ho
    Hu, Yang
    Hernandez, Michael
    Kim, Jin Ryoun
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2011, 414 (01) : 79 - 83
  • [32] Kinetic analysis of beta-amyloid fibril elongation
    Cannon, MJ
    Williams, AD
    Wetzel, R
    Myszka, DG
    ANALYTICAL BIOCHEMISTRY, 2004, 328 (01) : 67 - 75
  • [33] Salvianolic acid B inhibits fibril formation and neurotoxicity of amyloid beta-protein in vitro
    Tang, MK
    Zhang, JT
    ACTA PHARMACOLOGICA SINICA, 2001, 22 (04): : 380 - 384
  • [34] IN-VITRO AMYLOID FIBRIL FORMATION FROM ALPHA(1)-ANTITRYPSIN
    JANCIAUSKIENE, S
    CARLEMALM, E
    ERIKSSON, S
    BIOLOGICAL CHEMISTRY HOPPE-SEYLER, 1995, 376 (02): : 103 - 109
  • [35] Treatment with selective muscarinic MI agonist talsaclidine lowers the cerebrospinal fluid beta-amyloid levels in Alzheimer patients
    Hager, K
    Magdalena, A
    Raschig, A
    Müller-Spahn, E
    Eschweiler, G
    Heuser, I
    Hampel, H
    Müller-Thomsen, T
    Oertel, W
    Wienrich, M
    Signorell, A
    Gonzalez-Agosti, C
    Nitsch, RM
    Hock, C
    ZEITSCHRIFT FUR GERONTOLOGIE UND GERIATRIE, 2004, 37 : 6 - 7
  • [36] Rapid multiplexed detection of beta-amyloid and total-tau as biomarkers for Alzheimer's disease in cerebrospinal fluid
    Song, Chao
    Deng, Pan
    Que, Long
    NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE, 2018, 14 (06) : 1845 - 1852
  • [37] Cerebral changes and cerebrospinal fluid beta-amyloid in Alzheimer's disease: a study with quantitative magnetic resonance imaging
    Schroder, J
    Pantel, J
    Ida, N
    Essig, M
    Hartmann, T
    Knopp, MV
    Schad, LR
    Sandbrink, R
    Sauer, H
    Masters, CL
    Beyreuther, K
    MOLECULAR PSYCHIATRY, 1997, 2 (06) : 505 - 507
  • [38] SOLUBLE DERIVATIVES OF THE BETA-AMYLOID PROTEIN-PRECURSOR IN CEREBROSPINAL-FLUID - ALTERATIONS IN NORMAL AGING AND IN ALZHEIMERS-DISEASE
    PALMERT, MR
    USIAK, M
    MAYEUX, R
    RASKIND, M
    TOURTELLOTTE, WW
    YOUNKIN, SG
    NEUROLOGY, 1990, 40 (07) : 1028 - 1034
  • [39] In vitro toxicity of beta-amyloid
    Exley, C
    BIOCHEMICAL JOURNAL, 1996, 314 : 709 - 709
  • [40] Detection of glycerophospholipids and sphingolipids in urine and their correlation with cerebrospinal fluid beta-amyloid 42
    Fonteh, Alfred N.
    Cipolla, Matthew
    Chiang, Jiarong
    Castor, Katherine
    Harrington, Michael
    FASEB JOURNAL, 2016, 30
12345